Mahadeo, Kris MTewari, PritiParikh, Suhag HDriscoll, Timothy APage, KristinMartin, Paul LKurtzberg, JoannePrasad, Vinod K2022-03-232022-03-232015-111397-31421399-3046https://hdl.handle.net/10161/24646The use of HSCT is the only potentially curative treatment for CAMT, but access is limited by the availability of suitable donors. We report five consecutive patients with CAMT who received MAC and partially HLA-mismatched, UCBT (unrelated, n = 4). Median times to neutrophil (>500/μL) and platelet (≥20 000 and ≥50 000/μL) engraftment were 19, 57, and 70 days, respectively. Acute GvHD, grade II, developed in one patient, who subsequently developed limited chronic GvHD. At median follow-up of 14 yr, all patients are alive with sustained donor cell engraftment. To our knowledge, this is the largest single-center series of UCBT for patients with this disease and suggests that UCBT is a successful curative option for patients with CAMT.HumansThrombocytopeniaGraft vs Host DiseaseTreatment OutcomeTransplantation ConditioningCord Blood Stem Cell TransplantationFollow-Up StudiesAdolescentChildChild, PreschoolInfantInfant, NewbornFemaleMaleCongenital Bone Marrow Failure SyndromesJournal article2022-03-23